Metabolic syndrome X: A review

Canadian Journal of Cardiology

Volumn 16, Issue 6, 2000, Pages 779-789

  Timar, O ^a   Sestier, F ^a   Levy, Emile ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Coronary disease; Diabetes mellitus; Glucose; Hypertension; Insulin; Metabolism; Obesity; Syndrome X

Indexed keywords

FIBRINOGEN; GLUCOSE; INSULIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

BLOOD CLOTTING DISORDER; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; GLUCOSE INTOLERANCE; HYPERINSULINEMIA; HYPERURICEMIA; INSULIN RESISTANCE; METABOLIC DISORDER; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW;

BLOOD GLUCOSE; BLOOD PRESSURE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIPIDS; MALE; MICROVASCULAR ANGINA; RISK FACTORS;

EID: 0033924810     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (111)

1. Reaven GM. Banting lecture 1988. Rule of insulin resistance in human disease. Diabetes 1988;37:1595-607.
2. Reaven GM. Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care 1991;14:195-202.
3. Reaven GM. Syndrome X: 6 years later. J Intern Med Suppl 1994;736:13-22.
4. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991;14:173-94.
5. McKenney JM. Understanding and treating dyslipidemia associated with noninsulin-dependent diabetes mellitus and hypertension. Pharmacotherapy 1993;13:340-52.
6. Lemieux S, Despres JP. Metabolic complications of visceral obesity: contribution to the aetiology of type 2 diabetes and implications for prevention and treatment. Diabete Metab 1994;20:375-93.
7. Frayn KN, Coppack SW. Insulin resistance, adipose tissue and coronary heart disease. Clin Sci (Colch) 1992;82:1-8.
8. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75:473-86.
9. Nelson RG, Sievers ML, Knowler WC, et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 1990;81:987-95.
10. Proietto J, Filippis A, Nakhla C, Clark S. Nutrient-induced insulin resistance. Mol Cell Endocrinol 1999;151:143-9.
11. Chaour M, Theroux P, Gilfix BM, et al. 'True' fasting scrum insulin level, insulin resistance syndrome and coronary artery disease. Coron Artery Dis 1997;8:683-8.
12. Kahn CR, Vicent D, Doria A. Genetics of non-insulin-dependent (type-II) diabetes mellitus. Annu Rev Med 1996;47:509-31.
13. Granberry MC, Fonseca VA. Insulin resistance syndrome: options for treatment. South Med J 1999;92:2-15.
14. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-22.
15. Haffner SM, Mykkanen L, Valdez RA, Stern MP. Evaluation of two insulin assays in insulin resistance syndrome (syndrome X). Arterioscler Thromb 1994;14:1430-7.
16. Haffner SM, Mykkanen L, Valdez RA, et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab 1994;79:1806-10.
17. Haffner SM, Mykkanen L, Stern MP, Valdez RA, Heisserman JA, Bowsher RR. Relationship of proinsulin and insulin to cardiovascular risk factors in nondiabetic subjects. Diabetes 1993;42:1297-302.
18. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959-65.
19. Meigs JB, D'Agostino RB Sr, Wilson PW, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997;46:1594-600.
20. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81(4A):18B-25B.
21. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.
22. Eaton CB, Feldman HA, Assaf AR, et al. Prevalence of hypertension, dyslipidemia, and dyslipidemic hypertension. J Fam Pract 1994;38:17-23.
23. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
24. Austin MA, Hokanson JE, Edwards KL. Hyperrriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81(4A):7B-12B.
25. Gray RS, Robbins DC, Wang W, et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol 1997;17:2713-20.
26. Krauss RM, Williams PT, Lindgren FT, Wood PD. Coordinate changes in levels of human serum low and high density lipoprotein subclasses in healthy men. Arteriosclerosis 1988;8:155-62.
27. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM. LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes. Arterioscler Thromb 1992;12:1496-502.
28. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.
29. Reynisdottir S, Angelin B, Langin D, et al. Adipose tissue lipoprotein lipase and hormone-sensitive lipase. Contrasting findings in familial combined hyperlipidemia and insulin resistance syndrome. Arterioscler Thromb Vasc Biol 1997;17:2287-92.
30. Kissebah AH, Alfarsi S, Adams PW, Wynn V. Role of insulin resistance in adipose tissue and liver in the pathogenesis of endogenous hypertriglyceridaemia in man. Diabetologia 1976;12:563-71.
31. Bruce R, Godsland I, Walton C, Crook D, Wynn V. Associations between insulin sensitivity, and free fatty acid and triglyceride metabolism independent of uncomplicated obesity. Metabolism 1994;43:1275-81.
32. Despres JP. Groupement des facteurs de risque de maladie cardiovasculaire dans l'obésité abdominale. Revue Can Lipidol 1992:15-23.
33. Patsch JR, Karlin JB, Scott LW, Smith LC, Gotto AM Jr. Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia. Proc Natl Acad Sci USA 1983;80:1449-53.
34. Eisenberg S. Plasma lipoprotein conversions. Methods Enzymol 1986;129:347-66.
35. Tall AR, Small DM. Plasma high-density lipoproteins. N Engl J Med 1978;299:1232-6.
36. Marotti KR, Castle CK, Boyle TP, Lin AH, Murray RW, Melchior GW. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature 1993;364:73-5.
37. Glomset JA. Plasma lecithin: cholesterol acyltransferase. In: Nelson, GJ, ed. Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism. New York: Wiley-Interscience, 1972:745-87.
38. Soutar AK, Garner CW, Baker HN, et al. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: cholesterol acyltransferase. Biochemistry 1975;14:3057-64.
39. Ohta T, Saku K, Takata K, Nakamura R, Ikeda Y, Matsuda I. Different effects of subclasses of HDL containing apoA-I but not apoA-II (LpA-I) on cholesterol esterification in plasma and net cholesterol efflux from foam cells. Arterioscler Thromb Vasc Biol 1995;15:956-62.
40. Dobiasova M, Stribrna J, Sparks DL, Pritchard PH, Frohlich JJ. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb 1991;11:64-70.
41. Dieplinger H, Zechner R, Kostner GM. The in vitro formation of HDL2 during the action of LCAT: the role of triglyceride-rich lipoproteins. J Lipid Res 1985;26:273-82.
42. Swaney JB, Orishimo MW, Girard A. Enzymatically induced alterations in the structure of rat serum lipoproteins. J Lipid Res 1987;28:982-92.
43. Schernthaner G, Kostner GM, Dieplinger H, Prager R, Muhlhauser I. Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol acyltransferase activity in diabetes mellitus. Atherosclerosis 1983;49:277-93.
44. Mattock MB, Fuller JH, Maude PS, Keen H. Lipoproteins and plasma cholesterol esterification in normal and diabetic subjects. Atherosclerosis 1979;34:437-49.
45. Fielding CJ, Reaven GM, Fielding PE. Human noninsulin-dependent diabetes: identification of a defect in plasma cholesterol transport normalized in vivo by insulin and in vitro by selective immunoadsorption of apolipoprotein E. Proc Natl Acad Sci USA 1982;79:6365-9.
46. Bagdade JD, Lane JT, Subbaiah PV, Otto ME, Ritter MC. Accelerated cholesteryl ester transfer in noninsulin-dependent diabetes mellitus. Atherosclerosis 1993;104:69-77.
47. Taskinen MR, Beltz WF, Harper I, et al. Effects of NIDDM on very-low-density lipoprotein triglyceride and apolipoprotein B metabolism. Studies before and after sulfonylurea therapy. Diabetes 1986;35:1268-77.
48. Howard BV, Abbott WG, Beltz WF, et al. Integrated study of low density lipoprotein metabolism and very low density lipoprotein metabolism in non-insulin-dependent diabetes. Metabolism 1987;36:870-7.
49. Eto M, Watanabe K, Iwashima Y, et al. Increased frequency of apolipoprotem epsilon 4 allele in type II diabetes with hypercholesterolemia. Diabetes 1987;36:1301-6.
50. Eto M, Watanabe K, Sato T, Makino I. Apolipoprotein-E2 and hyperlipoproteinemia in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1989;69:1207-12.
51. Hussain MM, Maxfield FR, Mas-Oliva J, et al. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/alpha 2-macroglobulin reception. J Biol Chem 1991;266:13936-40.
52. Despres JP, Verdon MF, Moorjani S, et al. Apolipoprotein E polymorphism modifies relation of hyperinsulinemia to hypertriglyceridemia. Diabetes 1993;42:1474-81.
53. Zhao SP, Smelt AH, Van den Maagdenberg AM, et al. Plasma lipoprotein profiles of normocholesterolemic and hypercholesterolemic homozygotes for apolipoprotein E2(Arg158-Cys) compared. Clin Chem 1994;40:1559-66.
54. Selby JV, Newman B, Quiroga J, Christian JC, Austin MA, Fabsitz RR. Concordance for dyslipidemic hypertension in male twins. JAMA 1991;265:2079-84.
55. Williams RR, Hunt SC, Hopkins PN, et al. Familial dyslipidemic hypertension. Evidence from 58 Utah families for a syndrome present in approximately 12% of patients with essential hypertension. JAMA 1988;259:3579-86.
56. Modan M, Halkin H, Almog S, et al. Hyperinsulinemia. A link between hypertension obesity and glucose intolerance. J Clin Invest 1985;75:809-17.
57. Niskanen LK, Uusitupa Ml, Pyorala K. The relationship of hyperinsulinaemia to the development of hypertension in type 2 diabetic patients and in non-diabetic subjects. J Hum Hypertens 1991;5:155-9.
58. Shetterly SM, Rewers M, Hamman RF, Marshall JA. Patterns and predictors of hypertension incidence among Hispanics and non-Hispanic whites: the San Luis Valley Diabetes Study. J Hypertens 1994;12:1095-102.
59. Haffner SM, Ferrannini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992;20:38-45.
60. Mykkanen L, Kuusisto J, Haffner SM, Pyorala K, Laakso M. Fasting plasma insulin in relation to the development of hypertension in the elderly subjects. Circulation 1994;90(Suppl 2):665. (Abst)
61. Laakso M, Sarlund H, Mykkanen L. Essential hypertension and insulin resistance in non-insulin-dependent diabetes. Eur J Clin Invest 1989;19:518-26.
62. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987;317:350-7.
63. Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism 1990;39:167-74.
64. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992;231:235-40.
65. Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Hypertension 1993;21:136-41.
66. Tedde R, Sechi LA, Marigliano A, Pala A, Scano L. Antihypertensive effect of insulin reduction in diabetic-hypertensive patients. Am J Hypertens 1989;2:163-70.
67. Randeree HA, Omar MA, Motala AA, Seedat MA. Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. Diabetes Care 1992;15:1258-63.
68. Saad MF, Lillioja S, Nyomba BL, et al. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991;324:733-9.
69. Falkner B, Hulman S, Tannenbaum J, Kushner H. Insulin resistance and blood pressure in young black men. Hypertension 1990;16:706-11.
70. Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L. Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219-25.
71. Blaustein MP. Sodium ions, calcium ions, blood pressure regulation, and hypertension: a reassessment and a hypothesis. Am J Physiol 1977;232:C165-73.
72. + transport in skeletal muscle. Physiol Rev 1986;66:542-80.
73. - cotransport systems in essential hypertension. Hypertension 1987;10:14-10.
74. King GL, Goodman AD, Buzney S, Moses A, Kahn CR. Receptors and growth-promoting effects of insulin and insulinlike growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985;75:1028-36.
75. Kaiser N, Tur-Sinai A, Hasin M, Cerasi E. Binding, degradation, and biological activity of insulin in vascular smooth muscle cells. Am J Physiol 1985;249:E292-8.
76. Sowers JR, Epstein M. Diabetes mellitus and associated hypertension, vascular disease, and nephropathy. An update. Hypertension 1995;26:869-79.
77. Haffner SM. Progress in population analyses of the insulin resistance syndrome. Ann NY Acad Sci 1997;827:1-12.
78. Zimmet PZ, Alberti KG. The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet 1997;350(Suppl 1):SI1-4.
79. Grundy SM. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia. Am J Cardiol 1998;81(4A):1B-6B.
80. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-Americans. Diabetes 1995;44:1386-91.
81. Polonsky KS, Sturis J, Bell GI. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus -a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777-83.
82. Yki-Jarvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995;38:1378-88.
83. Garg A. Treatment of diabetic dyslipidemia. Am J Cardiol 1998;81(4A):47B-51B.
84. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9.
85. Peiris AN, Struve MF, Mueller RA, Lee MB, Kissebah AH. Glucose metabolism in obesity: influence of body fat distribution. J Clin Endocrinol Metab 1988;67:760-7.
86. Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest 1974;53:64-76.
87. Bogardus C, Lillioja S, Mott DM, Hollenheck C, Reaven G. Relationship between degree of obesity and in vivo insulin action in man. Am J Physiol 1985;248:E286-91.
88. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991;34:457-62.
89. Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-63.
90. Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA 1991;266:3008-11.
91. Zavaroni I, Mazza S, Fantuzzi M, et al. Changes in insulin and lipid metabolism in males with asymptomatic hyperuricaemia. J Intern Med 1993;234:25-30.
92. Jones SL, Close CF, Mattock MB, Jarrett RJ, Keen H, Viberti GC. Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria. BMJ 1989;298:487-90.
93. Niskanen L, Uusitupa M, Sarlund H, et al. Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1990;33:237-43.
94. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334:952-7.
95. Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2:154-60.
96. Webster MW, Scott RS. What cardiologists need to know about diabetes. Lancet 1997;350(Suppl 1):SI23-8.
97. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
98. Bierman EL. George Lyman Duff Memorial Lecture. Atherogenesis in diabetes. Arterioscler Thromb 1992;12:647-56.
99. Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998;81(4A):13B-17B.
100. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997;95:69-75.
101. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. Geneva: World Health Organization, 1998.
102. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 1993;269:3015-23.
103. Frohlich J, Fodor G, McPherson R, Genest J, Langner N. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. Can J Cardiol 1998;14(Suppl A):17A-21A.
104. Laws A, King AC, Haskell WL, Reaven GM. Relation of fasting plasma insulin concentration to high density lipoprotein cholesterol and triglyceride oncentrations in men. Arterioscler Thromb 1991;11:1636-42.
105. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1993;153:154-83.
106. Weber M, McNicoll S, Marcil M, et al. Metabolic factors clustering, lipoprotein cholesterol, apolipoprotein B, lipoprotein (a) and apolipoprotein E phenotypes in premature coronary artery disease in French Canadians. Can J Cardiol 1997;13:253-60.
107. Barth JD, Mancini GB. An update on lipid-lowering therapy. Curr Opin Lipidol 1995;6:32-7.
108. Storlien LH, Kriketos AD, Jenkins AB, et al. Does dietary fat influence insulin action? Ann NY Acad Sci 1997;827:287-301.
109. Renaud S, de Lorgeril M, Delaye J, et al. Cretan Mediterranean diet for prevention of coronary heart disease. Am J Clin Nutr 1995;61(6 Suppl):1360S-7S.
110. Dumesnil JG, Tremblay A, Despres JP, et al. Impact of a shift from high-carbohydrate to high-protein intake and satiety in overweight individuals. Int J Obes 1998;22(Suppl 3). (Abst)
111. Turner NC, Clapham JC. Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Prog Drug Res 1998;51:33-94.